Search research articles
Contact Us
Filters
Showing results (311-320 of 459) with videos related to
Page
of 46
Sort By:
The New England Journal of Medicine
|
November 13, 2018
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L Bhatt, P Gabriel Steg, Michael Miller, et al.
European Heart Journal
|
March 8, 2025
Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months
Robert A Byrne, Marco Valgimigli, Deepak L Bhatt, et al.
European Heart Journal
|
November 13, 2012
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis
Dharam J Kumbhani, P Gabriel Steg, Christopher P Cannon, et al.
Advanced Biology
|
August 10, 2024
Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System
Landys Lopez Quezada, Felix Mba Medie, Rebeccah J Luu, et al.
European Heart Journal
|
September 12, 2018
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
Gregg W Stone, Philippe Généreux, Robert A Harrington, et al.
The New England Journal of Medicine
|
September 8, 2006
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
Gilles Montalescot, Harvey D White, Richard Gallo, et al.
The American Journal of Cardiology
|
February 16, 2010
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
Christopher P Cannon, Karen E Rhee, Robert M Califf, et al.
Journal of the American Heart Association
|
May 6, 2020
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial
Baris Gencer, Xinmin S Li, Yared Gurmu, et al.
American Heart Journal
|
May 13, 2015
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial
Michelle L O'Donoghue, Ruchira Glaser, Philip E Aylward, et al.
Circulation
|
April 7, 2025
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
P Gabriel Steg, Michael Szarek, J Wouter Jukema, et al.
Page
of 46
Search research articles
Search
Showing results (311-320 of 459) with videos related to
Sort By:
Page
of 46
The New England Journal of Medicine
|
November 13, 2018
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L Bhatt, P Gabriel Steg, Michael Miller, et al.
European Heart Journal
|
March 8, 2025
Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months
Robert A Byrne, Marco Valgimigli, Deepak L Bhatt, et al.
European Heart Journal
|
November 13, 2012
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis
Dharam J Kumbhani, P Gabriel Steg, Christopher P Cannon, et al.
Advanced Biology
|
August 10, 2024
Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System
Landys Lopez Quezada, Felix Mba Medie, Rebeccah J Luu, et al.
European Heart Journal
|
September 12, 2018
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
Gregg W Stone, Philippe Généreux, Robert A Harrington, et al.
The New England Journal of Medicine
|
September 8, 2006
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
Gilles Montalescot, Harvey D White, Richard Gallo, et al.
The American Journal of Cardiology
|
February 16, 2010
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
Christopher P Cannon, Karen E Rhee, Robert M Califf, et al.
Journal of the American Heart Association
|
May 6, 2020
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial
Baris Gencer, Xinmin S Li, Yared Gurmu, et al.
American Heart Journal
|
May 13, 2015
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial
Michelle L O'Donoghue, Ruchira Glaser, Philip E Aylward, et al.
Circulation
|
April 7, 2025
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
P Gabriel Steg, Michael Szarek, J Wouter Jukema, et al.
Page
of 46